Theravance Biopharma US, Inc.
A biopharmaceutical company focused on delivering Medicines that Make a Difference® in patients’ and caregivers’ lives.
A biopharmaceutical company focused on delivering Medicines that Make a Difference® in patients’ and caregivers’ lives.
Theravance Biopharma US, Inc. is a biopharmaceutical company with a focus on delivering Medicines that Make a Difference® in patients' and caregivers' lives. Founded in 1996 as a spin-off of Theravance, Inc., the company is headquartered in the United States, with offices in South San Francisco and Dublin, Ireland. Theravance Biopharma is dedicated to transforming the treatment of specialty respiratory and neurologic diseases by leveraging decades of expertise. This has resulted in the development of FDA-approved YUPELRI® (revefenacin) for the maintenance treatment of chronic obstructive pulmonary disease (COPD). The company also has an internally discovered pipeline of programs to address unmet patient needs. With a collaborative and innovative culture, Theravance Biopharma invites individuals to explore job opportunities and learn more about the company. The latest investment of $100.50MPost-IPO Equity was made on 25 June 2021, indicating investor confidence in the company's potential for growth and impact in the biopharmaceutical industry. For more information, visit www.theravance.com.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Post-IPO Equity | $100.50M | - | 25 Jun 2021 | |
| Post-IPO Equity | $400.00M | - | 10 Feb 2020 | |
| Post-IPO Equity | $107.70M | - | 27 Apr 2016 | |
| Post-IPO Equity | $55.00M | 1 |
|
26 Oct 2015 |
| Venture Round | Unknown | 1 |
|
01 Jan 2000 |
No recent news or press coverage available for Theravance Biopharma US, Inc..
-logo.jpg){kind=logo}
We care about your data, and we'd love to use cookies make your experience better.
